A new device to improve radiation therapy for prostate and cervical cancer
The re-activatable Yb-169 radiation source: a therapeutic medical device to reduce the risk of brachytherapy and increase adoption
This study is testing a new medical device that uses a special type of radiation to make prostate cancer treatment more effective and cervical cancer treatment less invasive, helping patients get better care with fewer trips to the hospital.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pxalpha, LLC NIH-funded |
| Lab location | 1 site (Iowa City, UNITED STATES) |
| Project ID | NIH-10383611 on NIH RePORTER |
What this research studies
This research focuses on developing a novel medical device that utilizes a re-activatable radiation source to enhance the effectiveness of high-dose-rate brachytherapy for prostate cancer and to make treatment for cervical cancer less invasive. The approach aims to improve the precision of radiation delivery, thereby reducing the need for multiple procedures and hospital stays. By demonstrating the feasibility and commercial potential of this technology, the research seeks to facilitate its transition into clinical practice, ultimately improving patient access to effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with prostate or cervical cancer who are considering brachytherapy as a treatment option.
Not a fit: Patients with advanced cancer stages or those who are not candidates for brachytherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less invasive radiation therapy options for patients with prostate and cervical cancer.
How similar studies have performed: While this approach is innovative, similar advancements in brachytherapy have shown promise in improving treatment outcomes, suggesting potential for success.
Where this research is happening
Iowa City, UNITED STATES
- Pxalpha, LLC — Iowa City, United States (Active)
Researchers
- Principal investigator: Flynn, Ryan Thomas — Pxalpha, LLC
- Study coordinator: Flynn, Ryan Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.